ArticleJournal for immunotherapy of cancer2022

Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity.

Tailong Qu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.